1. Home
  2. CRBP vs THRY Comparison

CRBP vs THRY Comparison

Compare CRBP & THRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$7.54

Market Cap

184.4M

Sector

Health Care

ML Signal

HOLD

Logo Thryv Holdings Inc.

THRY

Thryv Holdings Inc.

HOLD

Current Price

$3.90

Market Cap

170.3M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBP
THRY
Founded
2009
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
184.4M
170.3M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
CRBP
THRY
Price
$7.54
$3.90
Analyst Decision
Strong Buy
Buy
Analyst Count
6
4
Target Price
$45.50
$9.33
AVG Volume (30 Days)
616.9K
979.7K
Earning Date
05-08-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.50
EPS
N/A
0.10
Revenue
$4,822,272.00
$785,015,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$116.00
N/A
P/E Ratio
N/A
$41.30
Revenue Growth
97.62
N/A
52 Week Low
$6.73
$1.91
52 Week High
$20.56
$14.28

Technical Indicators

Market Signals
Indicator
CRBP
THRY
Relative Strength Index (RSI) 34.94 56.40
Support Level N/A $3.14
Resistance Level $8.87 $4.17
Average True Range (ATR) 0.97 0.27
MACD -0.41 0.02
Stochastic Oscillator 4.17 69.56

Price Performance

Historical Comparison
CRBP
THRY

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About THRY Thryv Holdings Inc.

Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.

Share on Social Networks: